All In Biotech

Drug Trial Radar · NCT02272478

Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Jan 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,600

Planned (sponsor's estimate)

Start

Oct 30, 2014

Primary completion

Feb 2021

Study completion Feb 2022

Sponsor

Lead sponsor
Cardiff UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK
First posted
Oct 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years considered fit for an intensive chemotherapeutic approach, but younger patients who may not be considered suitable for the concurrent NCRI AML Trial for younger patients may also enter. Patients for whom intensive chemotherapy is not thought suitable may enter the concurrent NCRI trial of less intensive therapy (LI1). Approximately 1600 patients will be recruited. At entry, a randomisation will compare a standard chemotherapy schedule DA (Daunorubicin/Ara-C) combined with 1 dose of Mylotarg (gemtuzumab ozogamicin, or GO) in course 1 against CPX-351. Patients who have known adverse risk cytogenetics (using Grimwade 2010 classification favourable/intermediate/adverse) at diagnosis may enter a Phase 2 evaluation of the combination of Vosaroxin plus Decitabine. Patients who achieve complete remission (CR) and who are MRD negative by flow cytometry after course one of DA will receive one further course of DA, with a randomisation to receive, either a course of DA or intermediate dose Cytarabine (IDAC) as a third course. Patients who are MRD negative by flow cytometry after course one of CPX-351 will receive up to 2 further course of CPX. Patients who fail to achieve a CR after course 1 of DA or who are MRD positive by flow cytometry or for whom MRD information is not available, are eligible to be randomised to compare DA with DA plus Cladribine (DAC) or FLAG-Ida for up to two courses of therapy. Patients who fail to achieve a CR after course 1 of CPX-351 or who are MRD positive by flow cytometry or for whom MRD information is not available are eligible to be randomised between a second course of standard dose CPX versus a repeat of the course 1 schedule. Patients receiving Vosaroxin and Decitabine are excluded from these post course 1 randomisations . Following the outcome of course 1, patients who received DA chemotherapy on course 1 will be randomised to receive further chemotherapy with the 2nd generation FLT3 inhibitor AC220. Patients randomised to AC220 will be allocated a maximum of 3 courses (short AC220) or 3 courses plus maintenance for 1 year (long AC220). Patients receiving Vosaroxin and Decitabine are excluded from this randomisation. Patients will be eligible for a non-intensive allogeneic stem cell transplant if a suitable HLA matched donor is available.

Conditions

  • Acute Myeloid Leukaemia
  • Myelodysplastic Syndrome

Interventions

  • Arm A Mylotarg plus DA Versus CPX-351Drug

    Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.

  • Arm B Vosaroxin and DecitabineDrug

    If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.

  • Arm D Small molecule or NotDrug

    The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.

  • Arm C DA V FLAG-Ida V DACDrug

    If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.

  • Arm E CPX-351 (200 V 300)Drug

    If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).

  • Arm F DA V IDACDrug

    Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 1 year
  2. Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)Time frame: 1 month
  3. Duration of remission, relapse rates and deaths in first CRTime frame: 1 month
  4. Toxicity, both haematological and non-haematologicalTime frame: 1 month
  5. Supportive care requirements (and other aspects of health economics)Time frame: 6 months

Locations

87 sites in 2 countries. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Herlev and Gentofte Hospital

    Copenhagen, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital

    Odense, Denmark · Recruiting

  • Roskilde Hospital

    Roskilde, Denmark · Recruiting

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • Monklands Hospital

    Airdrie, United Kingdom · Recruiting

  • Ysbyty Gwynedd Hospital

    Bangor, United Kingdom · Recruiting

  • Royal United Hospital Bath

    Bath, United Kingdom · Recruiting

  • Belfast City Hospital

    Belfast, United Kingdom · Recruiting

  • Birmingham Heartland Hospital

    Birmingham, United Kingdom · Recruiting

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Recruiting

  • Blackpool Victoria Hospital

    Blackpool, United Kingdom · Recruiting

  • Ysbyty Glan Clwyd

    Bodelwyddan, United Kingdom · Recruiting

  • Pilgrim Hospital

    Boston, United Kingdom · Recruiting

  • Royal Bournemouth General Hospital

    Bournemouth, United Kingdom · Recruiting

  • Bradford Royal Infirmary

    Bradford, United Kingdom · Recruiting

  • Bristol Haematology & Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • UHW

    Cardiff, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • Cheltenham General Hospital

    Cheltenham, United Kingdom · Recruiting

  • Countess of Chester Hospital

    Chester, United Kingdom · Recruiting

  • St Richard's Hospital

    Chichester, United Kingdom · Recruiting

  • University Hospital of Coventry and Warwickshire

    Coventry, United Kingdom · Recruiting

  • Derby Teaching Hospital

    Derby, United Kingdom · Recruiting

  • Russell Hall

    Dudley, United Kingdom · Recruiting

  • Ninewells Hospital

    Dundee, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • Royal Devon & Exeter Hospital

    Exeter, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • Hairmyres Hospital

    Glasgow, United Kingdom · Recruiting

  • The New Victoria Hospital

    Glasgow, United Kingdom · Recruiting

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom · Recruiting

  • Royal Free Hospital

    Hamstead, United Kingdom · Recruiting

  • Raigmore Hospital

    Inverness, United Kingdom · Recruiting

  • Ipswich Hospital

    Ipswich, United Kingdom · Recruiting

  • Crosshouse & Ayr Hospital

    Irvine, United Kingdom · Recruiting

  • Kettering General Hospital

    Kettering, United Kingdom · Recruiting

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.